Literature DB >> 26279971

Systemic and Mucosal Immune Responses to Cryptosporidium-Vaccine Development.

Jacob G Ludington1, Honorine D Ward1.   

Abstract

Cryptosporidium spp is a major cause of diarrheal disease worldwide, particularly in malnourished children and untreated AIDS patients in developing countries in whom it can cause severe, chronic and debilitating disease. Unfortunately, there is no consistently effective drug for these vulnerable populations and no vaccine, partly due to a limited understanding of both the parasite and the host immune response. In this review, we will discuss our current understanding of the systemic and mucosal immune responses to Cryptosporidium infection, discuss the feasibility of developing a Cryptosporidium vaccine and evaluate recent advances in Cryptosporidium vaccine development strategies.

Entities:  

Keywords:  Cryptosporidium; immune response; mucosal; vaccine

Year:  2015        PMID: 26279971      PMCID: PMC4535728          DOI: 10.1007/s40475-015-0054-y

Source DB:  PubMed          Journal:  Curr Trop Med Rep


  110 in total

1.  Gliding motility leads to active cellular invasion by Cryptosporidium parvum sporozoites.

Authors:  Dawn M Wetzel; Joann Schmidt; Mark S Kuhlenschmidt; J P Dubey; L David Sibley
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

2.  Infection with Cryptosporidium hominis provides incomplete protection of the host against Cryptosporidium parvum.

Authors:  Abhineet Sheoran; Anthony Wiffin; Giovanni Widmer; Pradeep Singh; Saul Tzipori
Journal:  J Infect Dis       Date:  2012-01-25       Impact factor: 5.226

3.  Serum IgG response to Cryptosporidium immunodominant antigen gp15 and polymorphic antigen gp40 in children with cryptosporidiosis in South India.

Authors:  Sitara Swarna Rao Ajjampur; Rajiv Sarkar; Geneve Allison; Kalyan Banda; Anne Kane; Jayaprakash Muliyil; Elena Naumova; Honorine Ward; Gagandeep Kang
Journal:  Clin Vaccine Immunol       Date:  2011-02-02

Review 4.  DNA vaccines: roles against diseases.

Authors:  Kishwar Hayat Khan
Journal:  Germs       Date:  2013-03-01

5.  Mannose-binding lectin is a component of innate mucosal defense against Cryptosporidium parvum in AIDS.

Authors:  P Kelly; D L Jack; A Naeem; B Mandanda; R C Pollok; N J Klein; M W Turner; M J Farthing
Journal:  Gastroenterology       Date:  2000-11       Impact factor: 22.682

6.  Microarray analysis of the human antibody response to synthetic Cryptosporidium glycopeptides.

Authors:  Jamie Heimburg-Molinaro; Jeffrey W Priest; David Live; Geert-Jan Boons; Xuezheng Song; Richard D Cummings; Jan R Mead
Journal:  Int J Parasitol       Date:  2013-07-12       Impact factor: 3.981

7.  Human intestinal epithelial cells respond to Cryptosporidium parvum infection with increased prostaglandin H synthase 2 expression and prostaglandin E2 and F2alpha production.

Authors:  F Laurent; M F Kagnoff; T C Savidge; M Naciri; L Eckmann
Journal:  Infect Immun       Date:  1998-04       Impact factor: 3.441

Review 8.  C and CX3C chemokines: cell sources and physiopathological implications.

Authors:  Laura Stievano; Erich Piovan; Alberto Amadori
Journal:  Crit Rev Immunol       Date:  2004       Impact factor: 2.214

9.  Many chemokines including CCL20/MIP-3alpha display antimicrobial activity.

Authors:  De Yang; Qian Chen; David M Hoover; Patricia Staley; Kenneth D Tucker; Jacek Lubkowski; Joost J Oppenheim
Journal:  J Leukoc Biol       Date:  2003-09       Impact factor: 4.962

10.  Deficient serum mannose-binding lectin levels and MBL2 polymorphisms increase the risk of single and recurrent Cryptosporidium infections in young children.

Authors:  Marya Carmolli; Priya Duggal; Rashidul Haque; Janet Lindow; Dinesh Mondal; William A Petri; Phoenix Mourningstar; Catherine J Larsson; Meera Sreenivasan; Salwa Khan; B D Kirkpatrick
Journal:  J Infect Dis       Date:  2009-11-15       Impact factor: 5.226

View more
  8 in total

1.  Asparagine-Linked Glycans of Cryptosporidium parvum Contain a Single Long Arm, Are Barely Processed in the Endoplasmic Reticulum (ER) or Golgi, and Show a Strong Bias for Sites with Threonine.

Authors:  John R Haserick; Deborah R Leon; John Samuelson; Catherine E Costello
Journal:  Mol Cell Proteomics       Date:  2017-02-08       Impact factor: 5.911

2.  Cryptosporidium parvum vaccine candidates are incompletely modified with O-linked-N-acetylgalactosamine or contain N-terminal N-myristate and S-palmitate.

Authors:  John R Haserick; Joshua A Klein; Catherine E Costello; John Samuelson
Journal:  PLoS One       Date:  2017-08-08       Impact factor: 3.240

3.  Cryptosporidiosis in children in the Indian subcontinent.

Authors:  Malathi Murugesan; Santhosh Kumar Ganesan; Sitara Sr Ajjampur
Journal:  Trop Parasitol       Date:  2017 Jan-Jun

Review 4.  Lessons Learned from Protective Immune Responses to Optimize Vaccines against Cryptosporidiosis.

Authors:  Maxime W Lemieux; Karine Sonzogni-Desautels; Momar Ndao
Journal:  Pathogens       Date:  2017-12-24

Review 5.  Comparative Pathobiology of the Intestinal Protozoan Parasites Giardia lamblia, Entamoeba histolytica, and Cryptosporidium parvum.

Authors:  Andrew Hemphill; Norbert Müller; Joachim Müller
Journal:  Pathogens       Date:  2019-07-29

6.  The intestinal parasite Cryptosporidium is controlled by an enterocyte intrinsic inflammasome that depends on NLRP6.

Authors:  Adam Sateriale; Jodi A Gullicksrud; Julie B Engiles; Briana I McLeod; Emily M Kugler; Jorge Henao-Mejia; Ting Zhou; Aaron M Ring; Igor E Brodsky; Christopher A Hunter; Boris Striepen
Journal:  Proc Natl Acad Sci U S A       Date:  2021-01-12       Impact factor: 11.205

7.  Development of Two Mouse Models for Vaccine Evaluation against Cryptosporidiosis.

Authors:  Denise Ann Dayao; Justyna Jaskiewcz; Sangun Lee; Bruno Cesar Oliveira; Abhineet Sheoran; Giovanni Widmer; Saul Tzipori
Journal:  Infect Immun       Date:  2022-06-23       Impact factor: 3.609

8.  Adjuvant composition and delivery route shape immune response quality and protective efficacy of a recombinant vaccine for Entamoeba histolytica.

Authors:  Mayuresh M Abhyankar; Mark T Orr; Susan Lin; Mohammed O Suraju; Adrian Simpson; Molly Blust; Tiep Pham; Jeffrey A Guderian; Mark A Tomai; James Elvecrog; Karl Pedersen; William A Petri; Christopher B Fox
Journal:  NPJ Vaccines       Date:  2018-06-05       Impact factor: 7.344

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.